SAN DIEGO | January 8, 2026 — Just – Evotec Biologics, a collaboration between Evotec SE and Just – Evotec Biologics UK, has received a grant award to support the development of AI-driven optimization tools aimed at enhancing monoclonal antibody (mAb) developability for affordable global access. The initiative targets the integration of advanced computational algorithms into biologics discovery workflows to improve manufacturability, stability, and clinical progression of therapeutic antibodies.
Science Significance
The grant award empowers Just – Evotec Biologics to advance innovative technologies combining artificial intelligence (AI) and machine learning with biologics design, which is a growing frontier in drug discovery science. Monoclonal antibodies are among the most important therapeutic modalities for cancer, autoimmune disorders, and chronic diseases, yet their development is time- and resource-intensive due to challenges in optimizing expression, stability, aggregation, and immunogenicity. The use of AI-driven predictive models enables researchers to evaluate millions of molecular variants in silico, identify candidates with favorable biophysical properties, and reduce experimental burden. Such tools promise to transform early stage discovery by making the selection of clinically viable biologics more efficient, accelerating progression from lead identification to preclinical validation while conserving wet-lab resources.
Regulatory Significance
From a regulatory standpoint, the integration of AI into biologics development raises important considerations for data integrity, model validation, and documentation, especially when predictive algorithms influence candidate selection decisions that feed into filings like Investigational New Drug (IND) applications or Biologics License Applications (BLA). Authorities such as the FDA and EMA increasingly expect evidence of software quality, algorithm governance, and validation methods when AI systems are leveraged in regulated discovery workflows. The grant-funded project underscores the need for robust validation frameworks to ensure that predictions are scientifically defensible and that outputs are traceable and auditable — key elements of compliance within GxP systems. Establishing clear documentation and controls around AI tools strengthens confidence in data produced at scale and supports regulatory review readiness.
Business Significance
Advertisement
Strategically, securing public or philanthropic funding for AI research in biologics reinforces Just – Evotec’s position as a leader in cutting-edge drug discovery services. In a competitive biologics services market, the ability to offer AI-augmented developability assessment differentiates contract research and discovery platforms by providing value-added insights to partners and sponsors. For biotech and biopharma companies seeking to accelerate pipelines with limited internal computational capacity, such tools represent a compelling service offering. The grant also enhances Just – Evotec’s attractiveness to collaborators and investors focused on scalable technologies that can reduce time-to-clinic and overall R&D costs, potentially expanding market opportunities and long-term revenue streams.
Patients’ Significance
For patients, particularly those awaiting new biologics for unmet medical needs, innovations born from this grant have downstream implications that could improve treatment availability and affordability. By improving the efficiency of biologics discovery and decreasing the risk of late-stage attrition due to developability issues, AI-enabled workflows can lead to more therapeutic candidates entering clinical trials with greater confidence in their druglike properties. Enhanced developability also supports manufacturing consistency and may help lower production costs, which over time can influence pricing and access, especially for populations in low- and middle-income regions where affordability has historically limited access to advanced biologic therapies.
Policy Significance
At the policy level, the adoption of AI in regulated drug discovery reflects broader initiatives by governments and international agencies to foster innovation ecosystems that integrate digital technologies with life sciences. Policymakers are increasingly focused on creating guidelines for trustworthy AI in healthcare, balancing innovation with patient safety, transparency, and data governance. Grants that promote responsible AI usage in biologics development support policy goals related to economic competitiveness, scientific leadership, and equitable access to medicines. Successes from such programs can inform future frameworks that harmonize AI validation standards across jurisdictions, encouraging global alignment in technology-enabled health research.
The AI-driven optimization initiative at Just – Evotec Biologics represents a significant step in merging computational science with biologics discovery, addressing key barriers in the development of monoclonal antibodies. By advancing predictive algorithms that enhance developability, the project aligns scientific innovation with regulatory and quality considerations critical to the future of drug development. For the cGxP community, this underscores how digital transformation and AI adoption are set to shape regulated R&D workflows, influencing everything from early discovery choices to regulatory submissions and, ultimately, patient access to new therapies.
Source: Evotec SE press release
